Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Calvert

Showing results (211-220 of 220) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 220 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald, P A Vasey, L Adams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studiesChristopher R Calabrese, Michael A Batey, Huw D Thomas, et al.
Investigational New Drugs|January 1, 1996
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acidS Laohavinij, S R Wedge, M J Lind, et al.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancerM J Lind, S Ghazal-Aswad, L Gumbrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Biochimica Et Biophysica Acta|June 27, 2002
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanismG J Peters, H H J Backus, S Freemantle, et al.
Journal of Medicinal Chemistry|August 24, 2000
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profilesC E Arris, F T Boyle, A H Calvert, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Pageof 22

Showing results (211-220 of 220) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 220 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald, P A Vasey, L Adams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studiesChristopher R Calabrese, Michael A Batey, Huw D Thomas, et al.
Investigational New Drugs|January 1, 1996
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acidS Laohavinij, S R Wedge, M J Lind, et al.
British Journal of Cancer|November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanomaM R Middleton, J M Lunn, C Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancerM J Lind, S Ghazal-Aswad, L Gumbrell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumoursD S Boss, G K Schwartz, M R Middleton, et al.
Biochimica Et Biophysica Acta|June 27, 2002
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanismG J Peters, H H J Backus, S Freemantle, et al.
Journal of Medicinal Chemistry|August 24, 2000
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profilesC E Arris, F T Boyle, A H Calvert, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Pageof 22